Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs

Q: What insider transaction did Amneal Pharmaceuticals (AMRX) report for Tasos Konidaris?

Amneal reported that Executive Vice President & CFO Tasos Konidaris acquired restricted stock unit awards. He received a grant of 72,622 restricted stock units and 72,622 performance-based restricted stock units , each representing a contingent right to receive one share of Amneal Class A common stock.

Q: How many restricted stock units did the Amneal (AMRX) CFO receive in this Form 4 filing?

The Amneal CFO received 72,622 time-based restricted stock units and 72,622 performance-based restricted stock units . Each unit corresponds to a potential share of Class A common stock, subject to meeting time-based vesting or performance-based share price conditions described in the award terms.

Q: How do the performance-based restricted stock units for Amneal (AMRX) CFO work?

The performance-based restricted stock units are a 72,622 target-share grant that vests based on Amneal’s average closing share price over a three-year performance period. The payout can range from 0% to 200% of target, with any earned units vesting on February 28, 2029 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported equity awards of restricted stock units. He acquired 72,622 time-based restricted stock units and 72,622 performance-based restricted stock units, each representing a contingent right to receive one share of Amneal’s Class A common stock.

The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based restricted stock units are tied to Amneal’s average closing share price over a three-year performance period and can pay out from 0% to 200% of the 72,622 target shares, with any earned units vesting in full on February 28, 2029.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Konidaris Tasos

Role Executive Vice President & CFO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	72,622	$0.00	--
Grant/Award	Performance-Based Restricted Stock Units	72,622	$0.00	--

Holdings After Transaction: Restricted Stock Units — 72,622 shares (Direct); Performance-Based Restricted Stock Units — 72,622 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Konidaris Tasos

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Vice President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/02/2026		A		72,622		⁽²⁾	⁽²⁾	Class A Common Stock	72,622	$0	72,622	D
Performance-Based Restricted Stock Units	⁽³⁾	03/02/2026		A		72,622		⁽⁴⁾	⁽⁴⁾	Class A Common Stock	72,622	$0	72,622	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

4. Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Amneal Pharmaceuticals (AMRX) report for Tasos Konidaris?

Amneal reported that Executive Vice President & CFO Tasos Konidaris acquired restricted stock unit awards. He received a grant of 72,622 restricted stock units and 72,622 performance-based restricted stock units, each representing a contingent right to receive one share of Amneal Class A common stock.

How many restricted stock units did the Amneal (AMRX) CFO receive in this Form 4 filing?

The Amneal CFO received 72,622 time-based restricted stock units and 72,622 performance-based restricted stock units. Each unit corresponds to a potential share of Class A common stock, subject to meeting time-based vesting or performance-based share price conditions described in the award terms.

What is the vesting schedule for Tasos Konidaris’s time-based restricted stock units at Amneal (AMRX)?

The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. This means the award converts into Amneal Class A common shares gradually over four years, assuming continued satisfaction of the award’s service-based conditions.

How do the performance-based restricted stock units for Amneal (AMRX) CFO work?

The performance-based restricted stock units are a 72,622 target-share grant that vests based on Amneal’s average closing share price over a three-year performance period. The payout can range from 0% to 200% of target, with any earned units vesting on February 28, 2029.

What does each restricted stock unit represent in the Amneal (AMRX) Form 4 filing?

Each restricted stock unit and performance-based restricted stock unit represents a contingent right to receive one share of Amneal’s Class A common stock. Actual share delivery depends on satisfying the applicable vesting schedule and, for performance-based awards, achieving specified stock price performance targets.

When does the performance period for Amneal (AMRX) CFO’s performance-based RSUs end?

The performance period for the CFO’s performance-based restricted stock units ends on February 28, 2029. Any earned units, based on Amneal’s average closing share price performance, vest in full on that date, converting into shares of Class A common stock if performance conditions are met.